Désirée van der Heijde discusses the results of SELECT-AXIS 1, a phase II/III trial demonstrating that upadacitinib may be a promising treatment option for ankylosing spondylitis (2:27).
12-11-2019 | Ankylosing spondylitis | Video | Article
Désirée van der Heijde discusses the results of SELECT-AXIS 1, a phase II/III trial demonstrating that upadacitinib may be a promising treatment option for ankylosing spondylitis (2:27).